THALES
21.9.2020 09:02:42 CEST | Business Wire | Press release
Thales today announced the launch of the CipherTrust Data Security Platform , the industry’s first unified data protection solution that enables organisations to discover, protect, and control their most sensitive data wherever it resides. The new platform helps solve key challenges they face today. These include data security complexity caused by multi-cloud adoption, evolving global and regional privacy regulations, as well as the risk of data breaches from external and internal threats.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200921005046/en/
Drawing from years of data protection innovation, Thales has built the CipherTrust Data Security Platform to seamlessly unify data discovery, classification and data protection, along with strong access controls and centralised key management. The ‘all-in-one’ platform combines the best of Thales’s Vormetric and SafeNet KeySecure technologies to give organisations the power to keep sensitive data secure on premises or in the cloud while reducing costs and maintaining the highest levels of compliance assurance.
“CipherTrust Data Security Platform unifies the most critical elements of data security – data discovery, protection and control – into one integrated platform, providing powerful tools to address the evolving global and regional privacy regulations as well as the uptick of cloud adoption intensified by remote working,” said Todd Moore, Vice President, Encryption Solutions, Thales . “In addition to the external challenges of data protection, our new platform also helps reduce the operational complexities many organisations face, especially as businesses work to recover from the effects of the COVID-19 pandemic. This evolution of security through simplicity is exactly what organisations require now and for the future.”
Solving the Complexity Problem
Highly-distributed workforces, evolving regulations and technologies, infinite data growth and the exploding use of multi-cloud services puts sensitive data at risk, and makes data security even more challenging. According to the 2020 Thales Data Threat Report - Global Edition, organisations use 29 different cloud services on average. Lack of visibility and operational complexity has resulted in organisations not knowing where all of their sensitive data is stored. This concern around complexity (identified as the number one barrier to security by nearly 40% of the 2020 Thales Data Threat Report-Global Edition respondents) is simplified with the CipherTrust Data Security Platform.
“Complexity is one of the main barriers to deploying data security more broadly, in part because overall data security remains fairly specialised and siloed, forcing enterprises to manage multiple vendors and point products,” said Garrett Bekker, Senior Research Analyst, Information Security at 451 Research, part of S&P Global Market Intelligence, in the report, ‘Thales unites KeySecure and Vormetric product lines under CipherTrust Data Security Platform.’ “With the launch of CipherTrust Data Security Platform, Thales is looking to simplify the delivery of data security with one of the broadest data security portfolios in the market, spanning most flavours of encryption (application, database, server, file), vaulted and vaultless tokenisation, masking, key management, cloud key management, and HSMs and most recently, data discovery.”
Discover and classify sensitive data in the cloud and on-premises
As more enterprise applications and data move to the cloud and companies seek to improve scalability and deliver remote capabilities for their workforce, IT organisations will be challenged to have a holistic view of their data. As part of the platform, CipherTrust Data Discovery and Classification enables organisations to discover and classify sensitive data, as well as remediate, from a single pane of glass. Organisations can understand risks, uncover gaps, and make better decisions about both third-party data sharing and cloud migration. In addition, the solution provides a comprehensive set of built-in classification templates for commonly requested data privacy and security regulations, such as the GDPR and California Consumer Privacy Act (CCPA), but is flexible enough to handle custom policies based on specific patterns and algorithms.
Protect sensitive data anywhere with advanced encryption and tokenisation
According to IDC, more than 175 zetabytes of data will be created by 2025, and today more than half of all corporate data is stored in the cloud. To address the complexity of where data is stored, the CipherTrust Data Security Platform offers strong capabilities for securing and controlling access to sensitive data in databases, files and containers. Specific technologies include:
- CipherTrust Transparent Encryption – encrypts data across on-premises, cloud, database, file, and Big Data environments with comprehensive data access controls and detailed data access audit logging that can stop the most malicious attacks;
- CipherTrust Database Protection – provides transparent column-level encryption of structured, sensitive data residing in databases, such as credit card, social security numbers, national ID numbers, passwords and email addresses;
- CipherTrust Application Data Protection – offers APIs for developers to quickly add encryption and other crypto functions to their applications, while SecOps controls the encryption keys;
- CipherTrust Tokenisation– offers application-level data tokenisation services in two convenient solutions that deliver customer flexibility--Vaultless Tokenisation with policy-based Dynamic Data Masking and Vaulted Tokenisation; and
- CipherTrust Batch Data Transformation – provides static data masking services to remove sensitive data from production databases so compliance and security concerns are alleviated when sharing a database with third parties for analytics, testing, or other processing.
Control and centralise management of encryption keys
The accelerated adoption of encryption has led to the need to manage a far larger number of encryption keys across traditional data stores and multiple cloud environments. Proper management of encryption keys is paramount for data security because if keys are stolen, the encryption is rendered useless, and if they are lost the data is digitally shredded and cannot be recovered. This is why many organisations struggle with managing different key management solutions. CipherTrust Data Security Platform’s enterprise key management enables businesses to centrally manage and establish strong controls over encryption keys and policies for data encrypted on-premises and by cloud services. Specific technologies include:
- CipherTrust Manager– centralises keys, management and data access policies for all CipherTrust Data Security Platform products and is available in both physical and virtual form factors that are up to FIPS 140-2 Level 3 compliant;
- CipherTrust Cloud Key Manager – offers cloud bring you own key (BYOK) life cycle management for many Infrastructure, Platform- and Software as a Service cloud providers;
- CipherTrust KMIP Server – centralises key management for the standard Key Management Interoperability Protocol (KMIP) commonly used across storage solutions; and,
- CipherTrust TDE Key Manager – centralises key management for encryption found in Oracle, SQL, and Always Encrypted SQL.
Industry insight and views on the latest data security trends can be found on the Thales blog . Follow Thales on Twitter , LinkedIn , Facebook and YouTube .
About Thales Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a pro forma basis including Gemalto over 12 months). Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments. |
PLEASE VISIT
View source version on businesswire.com: https://www.businesswire.com/news/home/20200921005046/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
